Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2006 2
2007 1
2009 1
2010 2
2011 6
2012 3
2013 3
2016 3
2017 1
2019 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Successful Control of an Outbreak by Phenotypically Identified Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae in a Neonatal Intensive Care Unit.
Priante E, Minotti C, Contessa C, Boschetto M, Stano P, Dal Bello F, De Canale E, Lolli E, Baldo V, Baraldi E, Donà D. Priante E, et al. Among authors: dal bello f. Antibiotics (Basel). 2022 Nov 18;11(11):1649. doi: 10.3390/antibiotics11111649. Antibiotics (Basel). 2022. PMID: 36421293 Free PMC article.
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients.
Ungaro R, Taramasso L, Bruzzone B, Vicenti I, Galli L, Borghi V, Francisci D, Pecorari M, Zoncada A, Callegaro AP, Paolini E, Monno L, Bonora S, Di Biagio A; ARCA Study Group. Ungaro R, et al. Clin Microbiol Infect. 2019 Nov;25(11):1443-1446. doi: 10.1016/j.cmi.2019.07.004. Epub 2019 Jul 25. Clin Microbiol Infect. 2019. PMID: 31352080 Free article. No abstract available.
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors.
Andreis S, Basso M, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, Panese S, Rossi MC, Francavilla E, Boldrin C, Alvarez M, Dal Bello F, Mengoli C, Turriziani O, Sarmati L, Antonelli G, Andreoni M, Palù G, Parisi SG. Andreis S, et al. Among authors: dal bello f. J Glob Antimicrob Resist. 2017 Sep;10:106-112. doi: 10.1016/j.jgar.2017.05.011. Epub 2017 Jul 18. J Glob Antimicrob Resist. 2017. PMID: 28732792
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Parisi SG, Loregian A, Andreis S, Nannetti G, Cavinato S, Basso M, Scaggiante R, Dal Bello F, Messa L, Cattelan AM, Palù G. Parisi SG, et al. Among authors: dal bello f. Int J Infect Dis. 2016 Aug;49:151-3. doi: 10.1016/j.ijid.2016.06.020. Epub 2016 Jul 1. Int J Infect Dis. 2016. PMID: 27378577 Free article.
Virological testing of cerebrospinal fluid in children aged less than 14 years with a suspected central nervous system infection: A retrospective study on 304 consecutive children from January 2012 to May 2015.
Parisi SG, Basso M, Del Vecchio C, Andreis S, Franchin E, Bello FD, Pagni S, Biasolo MA, Manganelli R, Barzon L, Palù G. Parisi SG, et al. Among authors: bello fd. Eur J Paediatr Neurol. 2016 Jul;20(4):588-96. doi: 10.1016/j.ejpn.2016.04.002. Epub 2016 Apr 16. Eur J Paediatr Neurol. 2016. PMID: 27129875
Decreasing trends of drug resistance and increase of non-B subtypes amongst subjects recently diagnosed as HIV-infected over the period 2004-2012 in the Veneto Region, Italy.
Parisi SG, Andreis S, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, Panese S, Rossi MC, Francavilla E, Boldrin C, Dal Bello F, Basso M, Mengoli C, Andreoni M, Palù G. Parisi SG, et al. Among authors: dal bello f. J Glob Antimicrob Resist. 2013 Dec;1(4):201-206. doi: 10.1016/j.jgar.2013.05.008. Epub 2013 Jul 27. J Glob Antimicrob Resist. 2013. PMID: 27873613
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain. De Luca A, et al. J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11. J Infect Dis. 2013. PMID: 23315324
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group. Di Biagio A, et al. J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21. J Antimicrob Chemother. 2013. PMID: 22915463
27 results